Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Enter your email address below and subscribe to our newsletter

Sun Pharmaceutical has shared new Phase 4 clinical trial data, showcasing the efficacy of Cequa (cyclosporine ophthalmic solution) 0.09% in treating dry eye disease (DED). The results reveal that Cequa provides sustained improvements in patients whose symptoms were inadequately managed…

Bausch + Lomb has announced a major milestone in its sustainability efforts. Through its exclusive recycling initiatives—ONE by ONE Recycling and Biotrue Eye Care Recycling programs—the company has collected 94,119,275 units of used contact lenses, eye care products, and lens…

MediPrint Ophthalmics has revealed positive findings from its Phase 2b clinical trial for LL-BMT1, a 3D-printed, drug-eluting contact lens designed to treat mild to moderate glaucoma. These results, presented by Ian Ben Gaddie, OD, FAAO, at the American Academy of…

Atsena Therapeutics, Inc. and Nippon Shinyaku Co., Ltd. have entered an exclusive licensing agreement to advance and commercialize ATSN-101, an investigational gene therapy for Leber congenital amaurosis type 1 (LCA1), in both the United States and Japan. ATSN-101 is designed…

As the field of ophthalmology continues to advance, a plethora of international congresses offer opportunities for professionals to explore the latest innovations, share insights, and foster collaborations. Here is a comprehensive list of the top 15 international ophthalmology conferences scheduled…
MD Student Presents at American Academy of Ophthalmology Conference Elson S. Floyd College of Medicine Source: Author: | Date: 2024-10-28 07:00:00 Source: Author: | Date: 2024-10-28 07:00:00

Osheru announced the successful completion of a $4.7 million funding round aimed at accelerating the development and commercialization of its Ziplyft device for blepharoplasty surgery. The funding round was oversubscribed and led by a consortium of investors including individuals, family…

Genentech and Roche released compelling 2-year data from the phase 3 Pagoda and Pavilion studies evaluating Susvimo (ranibizumab injection) 100 mg/mL, marking a significant development in the treatment landscape for diabetic macular edema (DME) and diabetic retinopathy (DR). Reintroduction of…

Okyo Pharma announced its plan to initiate a phase 2 clinical trial for OK-101 in the treatment of neuropathic corneal pain (NCP), scheduled to begin in the third quarter of 2024. This one-year study follows promising results from preclinical animal…

NexThera has officially submitted a Phase 1/2a Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for NT-101, an innovative non-invasive eye drop treatment targeting wet age-related macular degeneration (wet AMD). Proprietary Delivery Platform: Advancing Treatment…